FDA Updates in Endocrinology

January 3, 2016

The end of the year brought many new FDA developments, including approval of a long-acting insulin and updated warnings for SGLT2 inhibitors.

Recent FDA news is outlined in the following slides.

Basaglar Wins FDA Approval - FDA alert.

FDA Eliminates REMS for Rosiglitazone-Containing Diabetes Medicines - FDA alert.

FDA Advisory Panel Against Expanded Indications for Ezetimibe - FDA alert. IMPROVE-IT trial.

FDA Updates of SGLT2 Inhibitors Labels - FDA alert.

FDA Approves Kanuma - FDA alert.

FDA Warns of Rare Cases of Underactive Thyroid in Infants - FDA alert.